FDA approves drug for autism irritability

Oct 13, 2006

The U.S. Food and Drug Administration approved Risperdal to treat irritability in autistic children and adolescents.

This is the first time the FDA approved a drug to treat behavior-related problems associated with autism in children, the FDA said in a news release. The drug can be used to treat aggression, deliberate self-injury and temper tantrums, all of which are classified under irritability.

Risperdal is an anti-psychotic drug used to treat adults with schizophrenia, the FDA said. In 2003, it was also approved as a short-term treatment for adults with acute manic episodes or extreme mood swings.

Risperdal is manufactured by Janssen Pharmaceutica N.V. in Beerse, Belgium.

Copyright 2006 by United Press International

Explore further: FDA approves hard-to-abuse narcotic painkiller

add to favorites email to friend print save as pdf

Related Stories

Advancing medicine, layer by layer

Jul 02, 2014

Personalized cancer treatments and better bone implants could grow from techniques demonstrated by graduate students Stephen W. Morton and Nisarg J. Shah, who are both working in chemical engineering professor ...

Bone marrow-on-a-chip unveiled

May 05, 2014

The latest organ-on-a-chip from Harvard's Wyss Institute for Biologically Inspired Engineering reproduces the structure, functions and cellular make-up of bone marrow, a complex tissue that until now could ...

Cutting cancer to pieces: New research on bleomycin

Apr 30, 2014

A variety of cancers are treated with the anti-tumor agent bleomycin, though its disease-fighting properties remain poorly understood. In a new study, lead author Basab Roy—a researcher at Arizona State ...

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

Jul 24, 2014

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

User comments : 0